Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with metastatic renal cell carcinoma (mRCC), even in patients who have coexisting acute kidney injury (AKI) or ...

A subgroup analysis by the International Metastatic RCC Database Consortium (IMDC) risk showed PFS and objective response rates favored Cabometyx in combination with Opdivo versus sunitinib ...

Adding plasma KIM-1 levels to the IMDC model improved prognostic performance to a C-index of 0.64. Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in RCC ...